Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Will Move MS Therapy Into Phase III After Fumapharm Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

Acquisition follows the release of positive Phase II study results of BG-12 in relapsing-remitting MS.

You may also be interested in...



Deals of the Week Plays Favorites: Our Deals Of The Year Winners!

We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.

Royalty Pharma Earns Its Profits The Slow Way

Paying cash up front to scientists, hospitals, biotechs and pharmas in exchange for their royalty stakes in successful drugs has proven profitable for Royalty Pharma. The firm has begun applying its long-term strategy to late-stage clinical candidates in addition to marketed products.

Biogen Idec CEO James Mullen: An Interview With “The Pink Sheet” DAILY

Company is “open for business” on deals, Mullen says during break at Massachusetts Biotechnology Council investor conference.

Related Content

Topics

UsernamePublicRestriction

Register

PS064252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel